Shenzhen - Delayed Quote CNY

Xiamen Kingdomway Group Company (002626.SZ)

Compare
14.89
+1.35
+(9.97%)
At close: 3:04:24 PM GMT+8
Loading Chart for 002626.SZ
  • Previous Close 13.54
  • Open 14.98
  • Bid 14.89 x --
  • Ask --
  • Day's Range 13.98 - 14.89
  • 52 Week Range 12.58 - 17.88
  • Volume 15,481,723
  • Avg. Volume 6,056,366
  • Market Cap (intraday) 9.082B
  • Beta (5Y Monthly) 1.20
  • PE Ratio (TTM) 36.32
  • EPS (TTM) 0.41
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (1.32%)
  • Ex-Dividend Date Jun 6, 2024
  • 1y Target Est 17.00

Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally. It offers its products under the Doctor's Best, Zipfizz, Kingdomway, Labrada, Prosupps, Maikon, and Jinlexin brands. The company was formerly known as Xiamen Jindawei Vitamin Co., Ltd. Xiamen Kingdomway Group Company was founded in 1997 and is based in Xiamen, China.

www.kingdomway.com

2,126

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002626.SZ

View More

Performance Overview: 002626.SZ

Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002626.SZ
1.39%
SSE Composite Index (000001.SS)
3.82%

1-Year Return

002626.SZ
5.40%
SSE Composite Index (000001.SS)
6.48%

3-Year Return

002626.SZ
45.67%
SSE Composite Index (000001.SS)
0.87%

5-Year Return

002626.SZ
21.37%
SSE Composite Index (000001.SS)
15.27%

Compare To: 002626.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002626.SZ

View More

Valuation Measures

Annual
As of 4/9/2025
  • Market Cap

    8.26B

  • Enterprise Value

    8.44B

  • Trailing P/E

    33.02

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.68

  • Price/Book (mrq)

    2.05

  • Enterprise Value/Revenue

    2.70

  • Enterprise Value/EBITDA

    23.97

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.13%

  • Return on Assets (ttm)

    3.81%

  • Return on Equity (ttm)

    6.47%

  • Revenue (ttm)

    3.12B

  • Net Income Avi to Common (ttm)

    253.95M

  • Diluted EPS (ttm)

    0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.09B

  • Total Debt/Equity (mrq)

    31.45%

  • Levered Free Cash Flow (ttm)

    79.19M

Research Analysis: 002626.SZ

View More

Company Insights: 002626.SZ

Research Reports: 002626.SZ

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.